Microarray gene expression profiling in acute myeloid leukemia
- VernacularTitle:急性粒细胞白血病基因表达谱的研究
- Author:
Yue LIU
;
Wenli MA
;
Fanyi MENG
;
Wenling ZHENG
- Publication Type:Journal Article
- Keywords:
acute myeloid Leukemia;
gene expression profiling;
microarray
- From:
Medical Journal of Chinese People's Liberation Army
2006;31(4):312-315
- CountryChina
- Language:Chinese
-
Abstract:
Objective In the treatment of acute myeloid leukemia (AML-M2a), the first CCR (continuous complete remission) has been one of the most critical indicators to the prognosis of the patients. Using microarray approaches, gene expression profiles have been studied in patients with different CCR, in order to find out the genes relevant to the progresses of the AML. Methods Bone marrow mononuclear cells were collected and used as different experimental groups respectively. Group A composed of three AML patients with CCR<6 months, while group B composed of three AML patients with CCR>12 months. mRNAs were purified and labeled with Cy3 and Cy5 respectively, which were used to hybridize against the Agilent human 1B 60mer oligonucleotide microarrays. Results In the 20173 genes tested, 21 genes were found expressed differentially between these two groups. Of these differentially expressed genes, 10 genes were up-regulated while 11 genes were down-regulated in group A. Conclusion Through microarray studies, 21 genes including APP were found to be differentially expressed in AML patients whom were treated with standard chemotherapy. Theses genes can be early indicators for the diagnosis as well as prognosis of the refractory AML.
